Boehringer Ingelheim acquires Nerio Therapeutics for US$ 1.3bn

Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio

Bristol Myers Squibb receives USFDA accelerated approval of Krazati in combination with Cetuximab for CRC

Second FDA approval for KRAZATI - reinforcing its potential across tumor types

AstraZeneca completes acquisition of Fusion Pharmaceuticals

This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs

AstraZeneca furthers ambition to transform outcomes in early lung cancer at ASCO 2024

Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings

Merck to showcase advances in the science of cancer with new data presented at ASCO 2024

Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors

Glenmark and BeiGene ink agreement for marketing and distribution of Tislelizumab and Zanubrutinib in India

AstraZeneca buys biopharmaceutical company Fusion

To accelerate the development of next-generation radioconjugates to treat cancer

Pfizer Oncology hosts innovation day

Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth

Ojjaara approved in the US as the first and only treatment for myelofibrosis patients with anaemia

Approval is for use in myelofibrosis patients with anaemia regardless of prior myelofibrosis therapy

Eugia Pharma signs voluntary license with Medicines Patent Pool to develop generic version of Nilotinib Capsules

The product will be produced at the Eugia Pharma Specialities, Unit-I, Medchal, Malkajgiri District, Telangana, India